Announcement of the Complete Agenda for the 2025 Frost & Sullivan New Investment Conference – Life Sciences New Investment Summit

The Frost & Sullivan Growth, Innovation and Leadership Best Practices (GIL) Awards aim to recognize outstanding companies that have made significant contributions and achieved leadership positions in various industries. After nearly 30 years of development globally, the authority and fairness of the awards have been widely recognized by the investment and financial communities, as well as within the industry. To date, more than 5,000 outstanding companies have been recognized globally.

The year 2025 marks the 64th anniversary of the establishment of Frost & Sullivan globally. Frost & Sullivan China will continue to track and research numerous successful cases of entrepreneurship, investment and financing in high-tech industries and strategic emerging industries within 2025. It will conduct objective and in-depth analysis, comprehensively evaluate the innovation capabilities, business models, founding teams, technical capabilities, and development prospects of the participating enterprises, and together with a professional judging committee, ultimately select several outstanding biotech leading enterprises. The results of the GIL Awards for 2025 will be grandly announced during this conference at the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards Ceremony and VIP Reception.

Highlights from the 2024 Frost & Sullivan Growth, Innovation and Leadership Awards Ceremony and VIP Reception

At the 2025 Frost & Sullivan New Investment Conference, the Global Life Sciences New Investment Summit Forum, Frost & Sullivan will release:

With continuous innovation in the global biopharmaceutical industry, antibody drugs are continuously expanding their application boundaries in areas such as oncology, autoimmune diseases, and rare diseases due to their advantages such as high specificity, high affinity, and low immunogenicity.

The successive emergence of new configurations such as bispecific antibodies, antibody-drug conjugates (ADCs), and nanobodies has enriched clinical treatment options and driven a profound reshaping of the industry competition landscape. As an important emerging force in biopharmaceutical innovation in China, driven by favorable policies, capital support, and technological innovation, the antibody industry has achieved a rapid leap from start-up to catch-up and then to independent innovation. Against this backdrop, it is of great significance for understanding industry development to systematically sort out the technological evolution, market scale, industry pattern, and development trends of the global and Chinese antibody industries by Frost & Sullivan.

Frost & Sullivan successfully released the 'Blue Book on the Current Development Status and Future Trends of the Medical Beauty Injection Product Industry' in 2024, which has attracted widespread attention within the industry. The article has received over 100,000 views and more than 10,000 downloads per copy. It has successfully linked with over 4,500 investment and financing institutions, effectively assisting in connecting upstream and downstream companies in the medical beauty sector with investment institutions, helping enterprises enhance their influence and gain greater attention in the capital market. To continuously track industry hotspots.

Frost & Sullivan will release the 'Blue Book on the Current Development and Future Trends of Medical Beauty Injection Products in China for 2025' at a parallel session to the New Investment Summit on Life Sciences - Devices on the Instrumentation Pavilion. The report will delve into the latest developments, market status and future trends of popular and emerging products in China's medical beauty injection product industry, uncover the huge potential of the industry, analyze the driving factors for market development, and aim to provide valuable references for corporate decision-makers, policymakers, investors and consumers within the industry. At the same time, it will provide a platform for companies to showcase their technical strength, market strategies and business advantages, promote knowledge sharing and best practice exchanges, and jointly stimulate the innovative vitality and continuous progress of China's medical beauty injection product industry. In addition, the English version of the Blue Book will also be published in mainstream global media to further enhance the company's global visibility and influence and support the company's internationalization strategy.

The 'White Paper on the Current Situation and Development Trends of the Mitochondrial Medicine Industry in 2025' written by Frost & Sullivan focuses on the field of mitochondrial medicine, delving into its core development context. It comprehensively analyzes the current industry situation, including key elements such as technological research and development progress, clinical application scope, market size, and growth trends. At the same time, it accurately predicts future development directions, providing comprehensive and in-depth strategic guidance for corporate decision-makers, policymakers, and investors in the mitochondrial medicine industry. This white paper aims to help all parties in the market gain an in-depth understanding of the environment of the mitochondrial medicine industry, clarify the competitive landscape, explore emerging market opportunities, and promote resource integration and collaborative innovation. It is hoped that through this platform, industry colleagues can work together to draw a new blueprint for the development of the mitochondrial medicine industry and jointly push the industry towards a more specialized, precise, and cutting-edge future.

With the acceleration of population aging, the upgrading of medical demand, and technological innovation, the market scale of medical devices in China and globally has shown a steady growth trend and will gradually unleash tremendous potential. According to data analysis by Frost & Sullivan, the market scale of medical devices in China has been climbing year by year in recent years, and it has risen to become the world's second-largest market after the United States.

The R&D and innovation capabilities of Chinese medical devices have steadily improved. The number of innovative medical devices approved for market launch by the National Medical Products Administration (NMPA) has been increasing year by year. The overseas recognition of Chinese brands has also risen. These factors have collectively driven Chinese medical device companies to expand into overseas markets, seeking broader growth space. Compared with the domestic market, overseas markets not only offer vast space but also tremendous growth potential in niche markets. At the same time, emerging markets have strong medical demand, providing Chinese companies with opportunities for differentiated competition. Chinese medical device products have strong competitiveness due to their high cost-effectiveness, innovation capabilities, and brand upgrades. Going global for Chinese medical devices has become an inevitable trend.

Frost & Sullivan has released the 'Blue Book on the Current Situation and Trends of Chinese Medical Devices Going Global in 2025', aiming to comprehensively analyze the current situation of Chinese medical devices going global, market prospects, challenges and opportunities faced. The blue book starts from the scale of the medical device market in China and globally, and analyzes the driving factors for Chinese medical device companies to go global from three aspects: internal factors, external factors, and strategic intentions. It also dissects the common strategies used by companies for going global; it analyzes various segments of the medical device market and key regions for going global, delves into the opportunities and challenges for Chinese medical device companies going global, and proposes targeted pain points and solutions to safeguard the go-global journey for enterprises and products.